Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity

Neuropharmacology

Volumn 46, Issue 2, 2004, Pages 202-210

  Bull, Eleanor J ^a   Hutson, Peter H ^b   Fone, Kevin C F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

1 (2,5 dimethoxy 4 iodophenyl) 2 aminopropane (DOI); 3,4 Methylenedioxymethamphetamine (MDMA); 5 HT 2A receptor; Elevated plus maze; Serotonin (5 HT); Social interaction

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; LOCOMOTION; MALE; MAZE TEST; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SOCIAL BEHAVIOR;

EID: 0346219341     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.08.004     Document Type: Article

References (46)

1. 3H]paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther. 242:1987;911-916.
2. Battaglia G., Sharkey J., Kuhar M.J., de Souza E.B. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse. 8:1991;249-260.
3. 2C receptor responsivity. Neuropharmacology. 44:2003;439-448.
4. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther. 254:1990;456-464.
5. Clemett D.A., Cockett M.I., Marsden C.A., Fone K.C. Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem. 71:1998;1271-1279.
6. 2A/2C binding sites in adult rat basal ganglia following lesions of serotonergic neurons. Brain Res. 793:1998;103-111.
7. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology. 114:1994;505-508.
8. Darmani N.A., Shaddy J., Gerdes C.F. Differential ontogenesis of three DOI-induced behaviors in mice. Physiol Behav. 60:1996;1495-1500.
9. File S.E. Behavioural detection of anxiolytic action. Elliot J.M., et al. Experimental Approaches to Anxiety and Depression. 1992;25-44 John Wiley, London.
10. 2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats. Br J Pharmacol. 96:1989;599-608.
11. Fone K.C.F., Robinson A.J., Marsden C.A. Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. Br J Pharmacol. 103:1991;1547-1555.
12. Fone K.C.F., Beckett S.R.G., Topham I.A., Swettenham J., Ball M., Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology. 159:2002;437-444.
13. Gold L.H., Hubner C.B., Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology. 99:1989;40-47.
14. Gordon C.J., Watkinson W.P., O'Callaghan J.P., Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav. 38:1991;339-344.
15. Granoff M.I., Ashby C.R. Jr. The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane (DOI). Neuropsychobiology. 37:1998;36-40.
16. Gurtman C.G., Morley K.C., Li K.M., Hunt G.E., McGregor I.S. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol. 446:2002;89-96.
17. Hemrick-Luecke S.K., Evans D.C. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis. Neuropharmacology. 42:2002;162-169.
18. Kaur P., Ahlenius S. Non-serotonergic potentiation by (-)-pindolol of DOI-induced forward locomotion in rats: possible involvement of beta-adrenoceptors? J Neural Transm. 107:2000;903-917.
19. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology. 23:2000;396-404.
20. McCann U.D., Ricaurte G.A. Lasting neuropsychiatric sequelae of (±)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol. 11:1991;302-305.
21. McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"): a controlled study in humans. Neuropsychopharmacology. 10:1994;129-138.
22. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
23. McGregor I.S., Clemens K.J., Van der Plasse G., Li K.M., Hunt G.E., Chen F., Lawrence A.J. Increased anxiety three months after brief exposure to MDMA ("ecstasy") in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology. 28:2003;1472-1482.
24. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology. 152:2000;230-248.
25. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., McGregor I.S. Increased anxiety and impaired memory function in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur J Pharmacol. 433:2001;91-99.
26. Nash J.F. Jr., Meltzer H.Y., Gudelsky G.A. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 245:1988;873-879.
27. 3H]serotonin from rat brain synaptosomes. J Med Chem. 25:1982;530-535.
28. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 8:1988;2788-2803.
29. Onaivi E.S., Bishop-Robinson C., Darmani N.A., Sanders-Bush E. Behavioral effects of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test. Life Sci. 57:1995;2455-2466.
30. Parrott A.C. Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacol. 16:2001;557-577.
31. Price L.H., Malison R.T., McDougle C.J., Pelton G.H., Heninger G.R. The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion. Biol Psychiatry. 43:1998;339-347.
32. 2A receptors in rat and human brain. Neuropsychopharmacology. 26:2002;387-396.
33. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 260:1988;51-55.
34. 2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology. 98:1989;495-499.
35. 2 receptors. Neuropharmacology. 31:1992;881-893.
36. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 240:1987;1-7.
37. Schmidt C.J., Kehne J.H. Neurotoxicity of MDMA: neurochemical effects. Ann N Y Acad Sci. 600:1990;665-680.
38. 1A agonists. J Pharmacol Exp Ther. 273:1995;101-112.
39. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry. 175:1999;63-69.
40. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 19:1998;427-441.
41. Stone D.M., Merchant K.M., Hanson G.R., Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology. 26:1987;1677-1683.
42. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
43. van de Wijngaart G.F. Drug problems among immigrants and refugees in The Netherlands and the Dutch health care and treatment system. Subst Use Misuse. 32:1997;909-938.
44. Wallis C.J., Lal H. A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Prog Neuropsychopharmacol Biol Psychiatry. 22:1998;547-565.
45. 2A receptor-mediated head shakes in rats. Psychopharmacology. 119:1995;9-14.
46. 2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J Neurosci. 22:2002;9635-9642.